Patent ID: 8883151

Claim:
A pharmaceutical formulation, comprising an aqueous solution of a glutamic acid buffer and an antibody or a fragment thereof comprising a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, wherein said antibody, or fragment thereof, specifically binds human IL-17 receptor A, and wherein: a) said formulation has a glutamic acid concentration of 10±0.2 mM; b) said formulation has a pH of 4.8±0.2; c) said formulation further comprises 3±0.2% proline (w/v) and 0.01±0.002% (w/v) polysorbate 20; d) said antibody is at a concentration of about 140±5% mg/ml; and e) said formulation has a viscosity of 5 to 7 cP at 25 degrees C.